Stay updated on Valoctocogene Roxaparvovec in Hemophilia A Clinical Trial

Sign up to get notified when there's something new on the Valoctocogene Roxaparvovec in Hemophilia A Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Valoctocogene Roxaparvovec in Hemophilia A Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the efficacy of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A patients.
    Difference
    0.2%
    Check dated 2024-06-06T14:32:24.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study. It now specifies that eligible participants are males aged 18 or older with hemophilia A and certain medical conditions, and provides both inclusion and exclusion criteria.
    Difference
    18%
    Check dated 2024-05-22T20:33:16.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:29:06.000Z thumbnail image

Stay in the know with updates to Valoctocogene Roxaparvovec in Hemophilia A Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Valoctocogene Roxaparvovec in Hemophilia A Clinical Trial page.